Stephen Alicanti > DLA Piper LLP (US) > New York, United States > Lawyer Profile
DLA Piper LLP (US) Offices
DLA Piper LLP (US)
1251 6TH AVE,
NEW YORK, NY 10020-1104
NEW YORK
United States
1251 6TH AVE,
NEW YORK, NY 10020-1104
NEW YORK
United States
Stephen Alicanti
Work Department
Corporate; Equity Capital Markets; Technology; Healthcare; Life Sciences; Insurance; Mergers and Acquisitions
Position
Partner
Lawyer Rankings
United States > Finance > Capital markets: equity offerings
(Next Generation Partners)DLA Piper LLP (US)
has an impressive mix of issuer and underwriter engagements in deals ranging from IPOs to follow-on offerings and at-the-market offerings, and is best known for mid-cap transactions. The team’s industry experience includes technology, healthcare and life sciences, consumer and retail, and industrials. Its broad national and international coverage brings it a wealth of domestic and global clients, including many Latin American issuers. New York’s Christopher Paci, who has strong connections to major underwriters, co-leads the US capital markets practice alongside Era Anagnosti in Washington DC. New York-based Stephen Alicanti has an impressive record, including in SPAC deals, while Seattle associate Bianca LaCaille is a team member on many of the firm’s key capital markets engagements.
Lawyer Rankings
- Next Generation Partners United States > Finance > Capital markets: equity offerings
- Capital markets: equity offerings United States > Finance
Top Tier Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Tax > International tax
- Real estate > Land use/zoning
- International trade and national security > CFIUS
- Investment fund formation and management > Alternative/hedge funds
- Media, technology and telecoms > Outsourcing
- Intellectual property > Patents: licensing
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Real estate > Real estate
- Government > State attorneys general
- Media, technology and telecoms > Telecoms and broadcast: regulatory
- Media, technology and telecoms > Telecoms and broadcast: transactions
Firm Rankings
- Media, technology and telecoms > Advertising and marketing: transactional and regulatory
- Insurance > Advice to insurers
- Industry focus > Cannabis
- Dispute resolution > E-discovery
- Tax > Financial products
- Finance > Fintech
- Intellectual property > Patents: litigation (full coverage)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Real estate > Real estate investment trusts (REITs)
- Energy > Renewable/alternative power
- Finance > Structured finance: securitization
- Media, technology and telecoms > Technology transactions
- Intellectual property > Trademarks: non-contentious (including prosecution, portfolio management and licensing)
- Tax > US taxes: contentious
- M&A/corporate and commercial > Venture capital and emerging companies
- Labor and employment > Workplace and employment counseling
- Antitrust > Cartel
- Intellectual property > Copyright
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Environment > Environment: regulatory
- Environment > Environment: transactional
- Insurance > Insurance: non-contentious
- Labor and employment > Labor and employment disputes (including collective actions)
- Labor and employment > Labor-management relations
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Media, technology and telecoms > Media and entertainment: transactional
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Dispute resolution > Product liability, mass tort and class action - defense: automotive/transport
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trademarks: litigation
- Tax > US taxes: non-contentious
- Finance > Capital markets: equity offerings
- Antitrust > Civil litigation/class actions: defense
- Real estate > Construction (including construction litigation)
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Environment > Environment: litigation
- Dispute resolution > General commercial disputes
- Government > Government contracts
- Dispute resolution > International arbitration
- Investment fund formation and management > Private equity funds (including venture capital)
- Healthcare > Service providers
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Project finance
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Transport > Rail and road: litigation and regulation
- International trade and national security > CFIUS